OR WAIT 15 SECS
The global growth hormone deficiency (GHD) area-covering the U.S., France, Germany, Italy, Spain, the UK, and Japan-is expected to rise to $2.08 billion by 2026, a 3.9% increase from around $1.42 billion, according to research and consulting firm GlobalData.
The latest report from GlobalData indicates that key drivers in growth include the launch of long-acting growth hormones, improved adherence to and compliance with the use of these growth hormones, and more awareness of the disease within the medical profession.
The company states that these long-acting growth hormones will eventually replace daily growth hormones, and will capture more than half of the latter’s patient share by the end of the forecast period. Among them, Pfizer/OPKO’s Lagova (hGH-CTP), Versartis’ somavaratan, and Novo Nordisk’s somapacitan will be the highest revenue earners by the end of the forecast period.
View the detailed report here.